Dr Reddy's Laboratories Ltd
NSE:DRREDDY

Watchlist Manager
Dr Reddy's Laboratories Ltd Logo
Dr Reddy's Laboratories Ltd
NSE:DRREDDY
Watchlist
Price: 1 214.45 INR 1.82% Market Closed
Market Cap: 1T INR
Have any thoughts about
Dr Reddy's Laboratories Ltd?
Write Note

Dr Reddy's Laboratories Ltd
Cash & Cash Equivalents

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Dr Reddy's Laboratories Ltd
Cash & Cash Equivalents Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Cash & Cash Equivalents CAGR 3Y CAGR 5Y CAGR 10Y
Dr Reddy's Laboratories Ltd
NSE:DRREDDY
Cash & Cash Equivalents
â‚ą7.1B
CAGR 3-Years
-22%
CAGR 5-Years
26%
CAGR 10-Years
N/A
Cipla Ltd
NSE:CIPLA
Cash & Cash Equivalents
â‚ą9.2B
CAGR 3-Years
-14%
CAGR 5-Years
-4%
CAGR 10-Years
16%
Sun Pharmaceutical Industries Ltd
NSE:SUNPHARMA
Cash & Cash Equivalents
â‚ą90.2B
CAGR 3-Years
7%
CAGR 5-Years
6%
CAGR 10-Years
4%
Zydus Lifesciences Ltd
NSE:ZYDUSLIFE
Cash & Cash Equivalents
â‚ą11.1B
CAGR 3-Years
8%
CAGR 5-Years
11%
CAGR 10-Years
7%
T
Torrent Pharmaceuticals Ltd
NSE:TORNTPHARM
Cash & Cash Equivalents
â‚ą11.5B
CAGR 3-Years
49%
CAGR 5-Years
14%
CAGR 10-Years
7%
M
Mankind Pharma Ltd
NSE:MANKIND
Cash & Cash Equivalents
â‚ą1.2B
CAGR 3-Years
-45%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Dr Reddy's Laboratories Ltd
Glance View

Market Cap
1T INR
Industry
Pharmaceuticals

Dr. Reddy's Laboratories Ltd., a prominent player in the global pharmaceutical landscape, has carved out a distinguished reputation for its commitment to producing high-quality medicines and innovative healthcare solutions. Founded in 1984 by Dr. K. Anji Reddy in Hyderabad, India, the company has expanded its reach across over 100 countries, including significant markets in the United States, Russia, and Europe. With a diverse portfolio that encompasses generic medications, active pharmaceutical ingredients (APIs), and proprietary pharmaceutical products, Dr. Reddy's stands as a reliable source for affordable healthcare options. Fuelled by a strong focus on research and development, the company invests heavily in cutting-edge technology and strives to address unmet medical needs in therapeutic segments such as oncology, cardiovascular disorders, and diabetes. For investors, Dr. Reddy's represents a robust opportunity in the fast-evolving healthcare sector. The company has consistently demonstrated resilience through its strategic alliances, a strong regulatory track record, and a growing pipeline of products. With the global generics market projected to expand significantly, Dr. Reddy's is well-positioned to leverage its expertise and operational efficiencies to capture new growth avenues. The company's emphasis on sustainability and corporate governance, exemplified by its responsible business practices, further enhances its appeal. With a strategic vision aimed at becoming a leading player in the pharmaceutical industry, Dr. Reddy's Laboratories is not just a company; it's a narrative of innovation and opportunity for investors seeking to make a meaningful impact in the healthcare domain.

DRREDDY Intrinsic Value
607.48 INR
Overvaluation 50%
Intrinsic Value
Price

See Also

What is Dr Reddy's Laboratories Ltd's Cash & Cash Equivalents?
Cash & Cash Equivalents
7.1B INR

Based on the financial report for Jun 30, 2024, Dr Reddy's Laboratories Ltd's Cash & Cash Equivalents amounts to 7.1B INR.

What is Dr Reddy's Laboratories Ltd's Cash & Cash Equivalents growth rate?
Cash & Cash Equivalents CAGR 5Y
26%

Over the last year, the Cash & Cash Equivalents growth was 23%. The average annual Cash & Cash Equivalents growth rates for Dr Reddy's Laboratories Ltd have been -22% over the past three years , 26% over the past five years .

Back to Top